- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01245712
Radiothérapie dans le traitement des patientes atteintes d'un cancer du sein de stade 0-II
Évaluation de l'esthétique et de la toxicité de l'irradiation partielle du sein à l'aide d'une irradiation par faisceau de protons
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Aperçu de l'étude
Statut
Les conditions
- Carcinome du sein invasif
- Cancer du sein de stade I AJCC v7
- Cancer du sein de stade IA AJCC v7
- Cancer du sein de stade IB AJCC v7
- Cancer du sein de stade II AJCC v6 et v7
- Cancer du sein de stade IIA AJCC v6 et v7
- Cancer du sein de stade IIB AJCC v6 et v7
- Adénocarcinome du sein
- Carcinome canalaire du sein in situ
- Cancer du sein de stade 0 AJCC v6 et v7
Description détaillée
PRIMARY OBJECTIVES:
I. To assess the cosmesis, acute toxicity and late toxicity in patients treated with accelerated partial breast irradiation delivered with proton radiation.
SECONDARY OBJECTIVES:
I. To evaluate the convenience of accelerated partial breast irradiation and quality of life during accelerated partial breast irradiation.
II. To estimate the in-breast tumor control rates in patients treated with accelerated partial breast irradiation delivered with proton radiation.
III. Compare dosimetry to alternate treatment modalities.
OUTLINE:
Within 10 weeks of last breast cancer surgery, patients undergo accelerated partial breast irradiation (APBI) delivered with proton radiation twice daily (BID) for 5 days.
After completion of study treatment, patients are followed up at 6 weeks, 6 months, 1 year, and 18 months, then annually for 10 years.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- M D Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Women who satisfy all of the following conditions are the only patients who will be eligible for this study.
-
The patient must consent to be in the study and must have signed an approved consent form conforming with federal and institutional guidelines.
-
Patients must be >/= 18 years old. (Adenocarcinoma of the breast is not seen in children)
-
English and non-English speaking patient
-
The patient must have stage 0, I, or II breast cancer. If stage II, the tumor size must be 3 cm or less.
-
On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the breast.
-
Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (DCIS and invasive).
Re-excision of surgical margins is permitted.
-
Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 3 cm or less. (Patients with microscopic multifocality are eligible as long as total pathologic tumor size is 3 cm or less.)
-
Patients with invasive breast cancer are required to have axillary staging which can include sentinel node biopsy alone (if sentinel node is negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes (if sentinel node is positive), or axillary dissection alone (with a minimum of 6 axillary nodes). Axillary staging is not required for patients with DCIS.
-
The target lumpectomy cavity must be clearly delineated and the target lumpectomy cavity/whole breast reference volume must be < 30% based on the postoperative/pre-enrollment CT scan.
-
Patients are eligible if, based on the postoperative CT scan, PBI is judged to be technically deliverable.
-
Patients with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to enrollment and are deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
Exclusion Criteria:
Women with one or more of the following conditions also are ineligible for this study.
- Men are not eligible for this study.
- Individuals that are considered to be cognitively impaired.
- T2 (> 3.0 cm), T3, stage III, or stage IV breast cancer.
- More than 3 histologically positive axillary nodes.
- Axillary nodes with definite evidence of microscopic or macroscopic extracapsular extension.
- Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes at time of enrollment unless there is histologic confirmation that these nodes are negative for tumor.
- Suspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benign.
- Non-epithelial breast malignancies such as sarcoma or lymphoma.
- Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters.
- Paget's disease of the nipple.
- Synchronous bilateral invasive or non-invasive breast cancer.
- Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re-excision, the patient is eligible.)
- Clear delineation of the extent of the target lumpectomy cavity not possible.
- Treatment plan that includes regional nodal irradiation.
- Prior radiation to the index breast
- Documented diagnosis of collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma.
- Pregnancy or lactation at enrollment.
- Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (APBI)
Within 10 weeks of last breast cancer surgery, patients undergo APBI delivered with proton radiation BID for 5 days. |
Ancillary studies
Autres noms:
Undergo APBI delivered with proton radiation
Autres noms:
Undergo APBI delivered with proton radiation
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient-Reported Cosmesis Score
Délai: 1 year
|
Patient-reported cosmesis score on the Breast Cancer Treatment Outcomes Scale (BCTOS) at 1 year. Cosmesis scores range from 1 (excellent) to 4 (poor), and scores of 3 (fair) or more indicate adverse cosmetic outcomes. |
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rate of CTCAE Grade 3+ Confluent Moist Desquamation
Délai: Within 6 weeks of radiation therapy
|
Rate of CTCAE grade 3+ confluent moist desquamation estimated within 6 weeks of radiation therapy with a 90% credible interval. If we observe CTCAE grade 3+ confluent moist desquamation in only 20 patients, then our 90% credible interval will be 7% to 13%. |
Within 6 weeks of radiation therapy
|
|
Percent of Patients with Local Failure
Délai: 10 years
|
Percent of patients with local failure at 10 years estimated with an exact 95% confidence interval. If there is 1 patient with local failure at 10 years, and researchers have follow-up on all patients at 10 years, then the upper limit of the exact 95% confidence interval will be 2.8%. If researchers don't have 10 years of follow-up on all patients researchers will use the product-limit estimator of Kaplan and Meier (1958) to estimate the local failure rate at 10 years. |
10 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Melissa Mitchell, MD, M.D. Anderson Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Maladies de la peau
- Maladies du sein
- Carcinome
- Tumeurs canalaires, lobulaires et médullaires
- Carcinome in situ
- Maladies de la peau et du tissu conjonctif
- Carcinome du sein in situ
- Tumeurs mammaires
- Carcinome intracanalaire non infiltrant
- Thérapeutique
- Phénomènes physiques
- Produits chimiques inorganiques
- Éléments
- Ions
- Électrolytes
- Radiothérapie
- Gaz
- Particules élémentaires
- Radiothérapie à ions lourds
- Cations, monovalente
- Cations
- Hydrogène
- Nucléons
- Protonothérapie
- Protons
Autres numéros d'identification d'étude
- 2009-0818
- 2009-0818 (Autre identifiant: M D Anderson Cancer Center)
- NCI-2011-01102 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .